Pablo Corral Highlights CRIC Study: Aspirin, Lipoprotein(a), and Cardiorenal Outcomes in CKD
Pablo Corral, Past President of Argentine Lipid Society, has shared a post on Linkedin:
“Primary Prevention Aspirin, Lipoprotein(a), and Cardiorenal Outcomes in Chronic Kidney Disease
New data from the CRIC study
In CKD patients without clinical CVD, aspirin use was associated with 38% lower MI risk and 28% lower ESRD risk — but only when Lp(a) ≥50 mg/dL.
No significant benefit was seen when Lp(a) <50 mg/dL, and bleeding risk did not increase.”
Title: Primary Prevention Aspirin, Lipoprotein(a), and Cardiorenal Outcomes in Chronic Kidney Disease: Chronic Renal Insufficiency Cohort
Authors: Alexander C. Razavi, Jing Chen, Wei Yang, Daohang Sha, Omar Dzaye, Harpreet S. Bhatia, Sotirios Tsimikas, James P. Lash, Mayank Kansal, Hernan Rincon-Choles, Viola Vaccarino, Terry A. Jacobson, Matthew J. Budoff, Roger S. Blumenthal, Seamus P. Whelton, Laurence S. Sperling, Michael J. Blaha, Jiang H
Read the full article here.
Read more on Hemostasis Today.
-
Aug 26, 2026, 10:09Gemma Figtree: How Well Do We Predict Heart Attack Risk in Women?
-
Aug 26, 2026, 10:06Understanding and Managing Fatigue in ITP – ITP Support Association
-
Aug 26, 2026, 10:04Abdul Muqtadir Abbasi: When a High INR Hides a Thrombotic Cancer
-
Aug 26, 2026, 09:42Mohammed Alo: What’s Wrong With the New Blood Pressure Guidelines?
-
Aug 26, 2026, 09:01Mary Cushman: The Role of IL-6 in Cardiovascular Disease
-
Aug 26, 2026, 07:49Linda Koch: Understanding Ageing Through Biological Transitions
-
Aug 26, 2026, 05:38Elias Lee։ Beyond MCA Stenosis – Recognizing Moyamoya
-
Aug 26, 2026, 03:46Hugo Ribeiro: Which NSAIDs Are Safest for Older Adults?
-
Aug 25, 2026, 19:45Cara T. Hoepner: Omega-3 is Not an Exposure